𝔖 Bobbio Scriptorium

✦ LIBER ✦

The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase

✍ Scribed by Masahide Yamamoto; Tetsuya Kurosu; Kazuhiko Kakihana; Daisuke Mizuchi; Osamu Miura

Book ID: 116288617
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 165 KB
Volume: 319
Category: Article
ISSN: 0006-291X
DOI: 10.1016/j.bbrc.2004.05.113

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The gatekeeper mutation T315I confers re

The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL

✍ Mian, A A; Schüll, M; Zhao, Z; Oancea, C; Hundertmark, A; Beissert, T; Ottmann, 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 465 KB

Drug resistance and BCR-ABL kinase domai

Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the fr

✍ Soverini, Simona; De Benedittis, Caterina; Papayannidis, Cristina; Paolini, Stef 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB